Integer Holdings Posts 8% Sales Growth in 2025, Tightens 2026 Outlook
Event summary
- Integer Holdings reported 8% sales growth and 21% adjusted EPS growth for full year 2025.
- Fourth quarter 2025 sales increased 5% to $472 million, with adjusted EBITDA up 11% to $106 million.
- Cardio & Vascular sales grew 17% year-over-year, driven by acquisitions and strong Neurovascular demand.
- Company repurchased 698,356 common shares for $50 million in Q4 2025.
- 2026 outlook maintains sales growth midpoint and high end of adjusted EPS growth from October outlook.
The big picture
Integer Holdings' strong 2025 performance reflects its strategic focus on acquisitions and organic growth in high-demand medical device segments. The company's ability to navigate regulatory headwinds and maintain its growth momentum will be critical as it aims to deliver sustainable long-term value. With a diverse portfolio and strong pipeline, Integer is positioning itself to capitalize on industry trends in cardio and vascular technologies.
What we're watching
- Execution Risk
- Whether Integer can sustain above-market organic sales growth in 2027 as projected.
- Financial Strategy
- How the company's share repurchase program will impact its leverage ratio and financial flexibility.
- Market Dynamics
- The pace at which the Cardio & Vascular segment can continue its strong growth trajectory.
Related topics